Navigation Links
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting

CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the first results from its collaboration with Pfizer Oncology to study early-stage renal cell carcinoma prognosis, which demonstrated a strong correlation between gene expression and recurrence risk in this patient population.  The study, which will be presented in an oral presentation tomorrow (8 – 9:30 a.m. CT) at the ASCO annual meeting in Chicago, could lead to the development of a multi-gene diagnostic test that estimates the risk of recurrence following surgery and that may ultimately aid in the subsequent identification of early-stage patients with renal cell carcinoma who could benefit most from treatment.

"Many early-stage renal cell carcinoma patients experience a recurrence of their cancer, yet there is currently no accurate means to identify the most aggressive cancers in advance," said Brian Rini, M.D., staff oncologist at Cleveland Clinic Taussig Cancer Institute and principle investigator on the study (i). "The strong correlation between gene expression and recurrence risk demonstrated in this study could help select the appropriate renal cell carcinoma patients for future drug development trials and potentially identify patients most likely to benefit from adjuvant therapy following surgery."

The study, "Identification of Prognostic Genomic Markers in Patients with Localized Clear Cell Renal Cell Carcinoma" (Abstract 4501), is the largest genomic analysis of localized clear cell renal carcinoma performed to date.  Additionally, it represents the first publicly presented results of Genomic Health's collaboration with Pfizer Oncology for assessing prognosis in patients with stage 1-3 renal carcinoma, clear cell type, that has not spread to other parts of the body.

Researchers evaluated more than 700 candidate genes from 942 stage 1-3 clear cell renal carcinoma patients treated at Cleveland Clinic between 1985 and 2003.  Genomic factors strongly associated with risk of recurrence and clinical/pathologic covariates were identified.  The magnitude of hazard ratios was comparable to those of other clinically used prognostic markers, such as estrogen-receptor status and HER2 status in breast cancer.  Researchers suggest that these results could be used to create a multi-gene algorithm to predict recurrence of early-stage renal cell carcinoma.

"Genomic Health's collaboration with Pfizer represents an industry-leading example of academic, diagnostic and therapeutic organizations combining resources and areas of expertise in order to advance the field of personalized medicine," said Steven Shak, M.D., chief medical officer, Genomic Health.  "Similar to what Genomic Health found using its quantitative RT-PCR technology in breast and colon cancers, this study shows that renal carcinoma tumors are not all the same and we believe this finding has the potential to provide critical insight for determining how early-stage renal cell carcinoma is treated in the future."  

The clear cell type of renal carcinoma is the most common type of kidney cancer in adults, affecting an estimated 25,000 people each year in the United States, and the incidence of the disease may be increasing.  As part of the collaboration, Genomic Health and Pfizer applied the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX® breast and colon cancer tests.

"We have the potential to individualize the treatment of early-stage renal cell carcinoma by assessing the risk of recurrence more accurately," said Isan Chen, M.D., Vice President - Genitourinary Tumor Strategy Team Leader, Pfizer Oncology Business Unit. "With a growing portfolio of kidney cancer therapies, Pfizer is committed to advancing the science and management of this disease.  Together with Genomic Health we intend to continue to define the clinical strategy and next steps for our work in renal cell carcinoma."

(i) Dr. Rini is also a member of the Pfizer scientific advisory board.  

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of March 31, 2010, more than 10,000 physicians in over 55 countries had ordered more than 148,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the study data could lead to the development of a multi-gene diagnostic test to estimate the recurrence risk in  renal cell carcinoma patients and possibly aid in the identification of patients who could most benefit from adjuvant  treatment, the belief that its collaboration with Pfizer represents an industry-leading example of combining resources and expertise to advance the field of personalized medicine, the belief that our prior development and commercialization strategy can be applied to renal cell carcinoma, our expectations regarding the size of the potential market, the continuation and success of our collaboration with Pfizer, and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of the collaborative arrangement; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Genomic Health to Announce First Quarter 2010 Financial Results and Host Conference Call on Wednesday, May 5, 2010
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
6. Transgenomic Reports Fourth Quarter Financial Results
7. AutoGenomics Announces the Launch of a Novel Test for B-RAF Mutations
8. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
9. AutoGenomics Receives ISO Certification
10. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
11. Genomic Health Announces Year-End 2009 Financial Results
Post Your Comments:
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
(Date:11/30/2015)... -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi , ... 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December 3, ... --> --> This will be ... ask the company questions in real-time - both in the ...
Breaking Medicine Technology:
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors Guide ... living, assisted living and all other retirement options. Support for issues surrounding the ... remains a top priority. , So it’s no surprise that every November, ...
(Date:11/30/2015)... Washington, DC (PRWEB) , ... ... ... Services, Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider ... valuable lessons learned from three innovative value-based care arrangements: Essentia Health and ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
(Date:11/30/2015)... ... 30, 2015 , ... Scott Newman MD, FACS of New ... plastic surgeons in the New York City area to utilize the new, non-invasive ... heat-induced laser treatment for fat loss in the abdomen, flanks, and other areas ...
Breaking Medicine News(10 mins):